Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 3/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1279255 | 1.00 | SLC1A1 (0.57) | SLC1A1LTA4HTACR1ALDH1A1CA1 | |
| SCHEMBL2059074 | 1.00 | SLC1A1 (0.57) | SLC1A1LTA4HTACR1ALDH1A1CA1 | |
| Hydrochloric Acid SCHEMBL5487502 | 0.98 | SLC1A1 (0.56) | SLC1A1LTA4HTACR1ALDH1A1CA1 | |
| Hydrochloric Acid SCHEMBL29886043 | 0.98 | SLC1A1 (0.56) | SLC1A1LTA4HTACR1ALDH1A1CA1 | |
| Hydrochloric Acid SCHEMBL5487507 | 0.98 | SLC1A1 (0.56) | SLC1A1LTA4HTACR1ALDH1A1CA1 | |
| Hydrochloric Acid SCHEMBL5926216 | 0.90 | SLC1A1 (0.48) | SLC1A1LTA4HPPARA | |
| SCHEMBL4449200 | 0.87 | SLC1A1 (0.46) | SLC1A1LTA4HTACR1 | |
| SCHEMBL589861 | 0.87 | SLC1A1 (0.46) | SLC1A1LTA4HTACR1 | |
| SCHEMBL7419155 | 0.87 | SLC1A1 (0.60) | SLC1A1LTA4HTACR1ALDH1A1CA1 | |
| SCHEMBL7419152 | 0.87 | SLC1A1 (0.60) | SLC1A1LTA4HTACR1ALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481484-B2 | Cyclic heptapeptide and use of the same | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2013-07-09 | — | — | US | disclosed |
| US-8242174-B2 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2012-06-21 | — | — | US | disclosed |
| US-20110269960-A1 | TRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-8022091-B2 | Triazole derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100286363-A1 | CYCLIC HEPTAPEPTIDE AND USE OF THE SAME | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100041655-A1 | TRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-1988083-A1 | TRIAZOLE DERIVATIVE | Taisho Pharmaceutical Co. Ltd. (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
| CN-101090723-A | Piperazine urea derivatives for the treatment of endometriosis | SCHERING AG (DE) | 2007-12-19 | — | — | CN | disclosed |
| EP-0988292-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-29 | — | — | EP | disclosed |
| US-5936089-A | PIPERIDINE DERIVATIVES; BONE DISORDERS; OBESITY; AGING; CACHEXIA ASSOCIATED WITH AIDS AND CANCER | PFIZER INC (US) | 1999-08-10 | — | — | US | disclosed |
| CN-1206422-A | Growth-hormone secretagogues | PFIZER (US) | 1999-01-27 | — | — | CN | disclosed |
| WO-1998058949-A1 | TREATMENT OF INSULIN RESISTANCE WITH GROWTH HORMONE SECRETAGOGUES | PFIZER PRODUCTS INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| WO-1998056771-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-17 | — | — | WO | disclosed |
| EP-0869968-A1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0828754-A1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER INC. (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1997024369-A1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1996038471-A1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER INC. (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996035713-A1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER, INC. (US) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269960-A1 | TRIAZOLE DERIVATIVE | S1PR3, S1PR1, S1PR5 | SLC1A1 1164/4885LTA4H 1329/4885TACR1 114/4885 |
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | ANTXR2, AGXT, AADAC | SLC1A1 557/4885LTA4H 2308/4885TACR1 3386/4885 |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | SLC1A1 1352/4885LTA4H 3356/4885TACR1 1124/4885 |
| US-20100041655-A1 | TRIAZOLE DERIVATIVE | S1PR3, S1PR1, S1PR5 | SLC1A1 1227/4885LTA4H 1186/4885TACR1 117/4885 |
| US-20100286363-A1 | CYCLIC HEPTAPEPTIDE AND USE OF THE SAME | FABP4, HDGF, EBP | SLC1A1 4021/4885LTA4H 1136/4885TACR1 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.